Abstract
Original language | English |
---|---|
Pages (from-to) | 1049-1069 |
Number of pages | 21 |
Journal | EuroIntervention |
Volume | 16 |
Issue number | 13 |
DOIs | |
Publication status | Published - 2021 |
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
An EAPCI expert consensus document on ischaemia with non-obstructive coronary arteries in collaboration with european society of cardiology working group on coronary pathophysiology & microcirculation endorsed by coronary vasomotor disorders international study group. / Kunadian, Vijay; Chieffo, Alaide; Camici, Paolo G. et al.
In: EuroIntervention, Vol. 16, No. 13, 2021, p. 1049-1069.Research output: Contribution to journal › Review article › Academic › peer-review
TY - JOUR
T1 - An EAPCI expert consensus document on ischaemia with non-obstructive coronary arteries in collaboration with european society of cardiology working group on coronary pathophysiology & microcirculation endorsed by coronary vasomotor disorders international study group
AU - Kunadian, Vijay
AU - Chieffo, Alaide
AU - Camici, Paolo G.
AU - Berry, Colin
AU - Escaned, Javier
AU - Maas, Angela H. E. M.
AU - Prescott, Eva
AU - Karam, Nicole
AU - Appelman, Yolande
AU - Fraccaro, Chiara
AU - Buchanan, Gill Louise
AU - Manzo-Silberman, Stephane
AU - Al-Lamee, Rasha
AU - Regar, Evelyn
AU - Lansky, Alexandra
AU - Abbott, J. Dawn
AU - Badimon, Lina
AU - Duncker, Dirk J.
AU - Mehran, Roxana
AU - Capodanno, Davide
AU - Baumbach, Andreas
N1 - Funding Information: Vijay Kunadian reports other from Bayer, other from Amgen, other from Abbott, other from Astra Zeneca, other from Daiichi Sankyo, outside the submitted work; and Vijay Kunadian is supported by an external research grant from Astra Zeneca (funder reference number ISSBRIL0303). Vijay Kunadian is also supported/funded by the National Institute for Health Research Newcastle Biomedical Research Centre based at Newcastle Hospitals NHS Foundation Trust and Newcastle University. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. Vijay Kunadian also supported by the British Heart Foundation Clinical Study Grant CS/15/7/31679 for the British Heart Foundation older patients with non-ST SEgmeNt elevatIOn myocaRdial infarction Randomised Interventional TreAtment Trial. Alaide Chieffo reports personal fees from Abiomed, personal fees from Biosensor, personal fees from Abbott, personal fees from Cardinal Health, personal fees from Magenta, outside the submitted work. Paolo G. Camici reports personal fees from Servier, during the conduct of the study. Colin Berry reports grants, non-financial support and other from Abbott Vascular, grants, non-financial support and other from AstraZeneca, non-financial support from Boehringer Ingelheim, grants and non-financial support from GSK, grants, non-financial support and other from HeartFlow, non-financial support and other from Opsens, grants, non-financial support and other from Novartis, non-financial support from Siemens Healthcare, outside the submitted work; and Colin Berry acknowledges research support from the British Heart Foundation (PG/17/ 2532884; FS/17/26/32744; RE/18/6134217) and Medical Research Council (MR/S005714/1). Javier Escaned reports personal fees from Abbott, personal fees from Philips, outside the submitted work. Angela H.E.M. Maas has nothing to disclose. Eva Prescott has nothing to disclose. Nicole Karam has nothing to disclose. Yolande Appelman has nothing to disclose. Chiara Fraccaro has nothing to disclose. Gill Louise Buchanan reports grants and personal fees from Bayer, grants and personal fees from Pfizer, grants and personal fees from Daichii-Sanyo, grants from Menarini, outside the submitted work. Stephane Manzo-Silberman has nothing to disclose. Rasha Al-Lamee reports other from Philips Volcano, other from Menarini, outside the submitted work. Evelyn Regar has nothing to dis-close. Alexandra Lansky has nothing to disclose. J. Dawn Abbott has nothing to disclose. Lina Badimon reports grants from AstraZeneca, other from Sanofi, grants from A-Biotics, other from Lilly, other from Astra-Zeneca, other from Research Forum on Beer and Lyfestyle, other from Research Forum on Beer and Lyfestyle, other from Pfizer, outside the submitted work. Dirk J. Duncker reports grants from Dutch Heart Foundation, outside the submitted work. Roxana Mehran reports grants from Abbott Laboratories, grants from AstraZeneca, grants from Bayer, grants from Beth Israel Deaconess, grants from BMS, grants from CSL Behring, grants from DSI, grants from Medtronic, grants from Novartis Pharmaceuticals, grants from OrbusNeich, personal fees from Abbott Laboratories, other from Abbott Laboratories, other from Abiomed, other from The Medicines Company, personal fees from Boston Scientific, personal fees from Medscape/WebMD, personal fees from Siemens Medical Solutions, personal fees from PLx Opco Inc/dba PLx Pharma Inc, non-financial support and other from Regeneron Pharmaceuticals, personal fees from Roivant Sciences, other from Spectranetics/Philips/Volcano Corp, personal fees from Sanofi, personal fees from Medtelligence (Janssen Scientific Affairs), personal fees from Janssen Scientific Affairs, other from Bristol Myers Squibb, other from Watermark Research Partners, other from Claret Medical, other from Elixir Medical, outside the submitted work. Davide Capodanno has nothing to disclose. Andreas Baumbach has nothing to disclose. Funding Information: 12. Bergmann SR, Hack S, Tewson T, Welch MJ and Sobel BE. The dependence of accumulation of 13NH3 by myocardium on metabolic factors and its implications for quantitative assessment of perfusion. Circulation. 1980;61:34-43. 13. Bergmann SR, Fox KA, Rand AL, McElvany KD, Welch MJ, Markham J and Sobel BE. Quantification of regional myocardial blood flow in vivo with H215O. Circulation. 1984;70:724-33. 14. Senthamizhchelvan S, Bravo PE, Esaias C, Lodge MA, Merrill J, Hobbs RF, Sgouros G and Bengel FM. Human biodistribution and radiation dosimetry of 82Rb. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2010;51:1592-9. 15. Berman DS, Maddahi J, Tamarappoo BK, Czernin J, Taillefer R, Udelson JE, Gibson CM, Devine M, Lazewatsky J, Bhat G and Washburn D. Phase II safety and clinical comparison with single-photon emission computed tomography myocardial perfusion imaging for detection of coronary artery disease: flurpiridaz F 18 positron emission tomography. Journal of the American College of Cardiology. 2013;61:469-477. 16. Kaufmann PA, Gnecchi-Ruscone T, Yap JT, Rimoldi O and Camici PG. Assessment of the reproducibility of baseline and hyperemic myocardial blood flow measurements with 15O-labeled water and PET. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 1999;40:1848-56. 17. Nagamachi S, Czernin J, Kim AS, Sun KT, Bottcher M, Phelps ME and Schelbert HR. Reproducibility of measurements of regional resting and hyperemic myocardial blood flow assessed with PET. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 1996;37:1626-31. 18. Doyle M, Weinberg N, Pohost GM, Bairey Merz CN, Shaw LJ, Sopko G, Fuisz A, Rogers WJ, Walsh EG, Johnson BD, Sharaf BL, Pepine CJ, Mankad S, Reis SE, Vido DA, Rayarao G, Bittner V, Tauxe L, Olson MB, Kelsey SF and Biederman RW. Prognostic value of global MR myocardial perfusion imaging in women with suspected myocardial ischemia and no obstructive coronary disease: results from the NHLBI-sponsored WISE (Women's Ischemia Syndrome Evaluation) study. JACC Cardiovascular imaging. 2010;3:1030-6. 19. Christian TF, Aletras AH and Arai AE. Estimation of absolute myocardial blood flow during first-pass MR perfusion imaging using a dual-bolus injection technique: comparison to single-bolus injection method. Journal of magnetic resonance imaging : JMRI. 2008;27:1271-7. 20. Goldstein TA, Jerosch-Herold M, Misselwitz B, Zhang H, Gropler RJ and Zheng J. Fast mapping of myocardial blood flow with MR first-pass perfusion imaging. Magnetic resonance in medicine. 2008;59:1394-400. 21. Hsu LY, Rhoads KL, Holly JE, Kellman P, Aletras AH and Arai AE. Quantitative myocardial perfusion analysis with a dual-bolus contrast-enhanced first-pass MRI technique in humans. Journal of magnetic resonance imaging : JMRI. 2006;23:315-22. 22. Motwani M, Jogiya R, Kozerke S, Greenwood JP and Plein S. Advanced cardiovascular magnetic resonance myocardial perfusion imaging: high-spatial resolution versus 3-dimensional whole-heart coverage. Circulation Cardiovascular imaging. 2013;6:339-48. 23. Corcoran D, Ford TJ, Hsu LY, Chiribiri A, Orchard V, Mangion K, McEntegart M, Rocchiccioli P, Watkins S, Good R, Brooksbank K, Padmanabhan S, Sattar N, McConnachie A, Oldroyd KG, Touyz RM, Arai A and Berry C. Rationale and design of the Coronary Microvascular Angina Cardiac Magnetic Resonance Imaging (CorCMR) diagnostic study: the CorMicA CMR sub-study. Open heart. 2018;5:e000924. 24. Thomson LE, Wei J, Agarwal M, Haft-Baradaran A, Shufelt C, Mehta PK, Gill EB, Johnson BD, Kenkre T, Handberg EM, Li D, Sharif B, Berman DS, Petersen JW, Pepine CJ and Bairey Merz CN. Cardiac magnetic resonance myocardial perfusion reserve index is reduced in women with coronary microvascular dysfunction. A National Heart, Lung, and Blood Institute-sponsored study from the Women's Ischemia Syndrome Evaluation. Circulation Cardiovascular imaging. 2015;8. 25. Liu A, Wijesurendra RS, Liu JM, Forfar JC, Channon KM, Jerosch-Herold M, Piechnik SK, Neubauer S, Kharbanda RK and Ferreira VM. Diagnosis of Microvascular Angina Using Cardiac Magnetic Resonance. Journal of the American College of Cardiology. 2018;71:969-979. 26. Kotecha T, Martinez-Naharro A, Boldrini M, Knight D, Hawkins P, Kalra S, Patel D, Coghlan G, Moon J, Plein S, Lockie T, Rakhit R, Patel N, Xue H, Kellman P and Fontana M. Automated Pixel-Wise Quantitative Myocardial Perfusion Mapping by CMR to Detect Obstructive Coronary Artery Disease and Coronary Microvascular Dysfunction: Validation Against Invasive Coronary Physiology. JACC Cardiovascular imaging. 2019. 27. CT coronary angiography in patients with suspected angina due to coronary heart disease (SCOT-HEART): an open-label, parallel-group, multicentre trial. Lancet (London, England). 2015;385:2383-91. 28. Newby DE, Adamson PD, Berry C, Boon NA, Dweck MR, Flather M, Forbes J, Hunter A, Lewis S, MacLean S, Mills NL, Norrie J, Roditi G, Shah ASV, Timmis AD, van Beek EJR and Williams MC. Coronary CT Angiography and 5-Year Risk of Myocardial Infarction. The New England journal of medicine. 2018;379:924-933. 29. Williams MC, Hunter A, Shah A, Assi V, Lewis S, Mangion K, Berry C, Boon NA, Clark E, Flather M, Forbes J, McLean S, Roditi G, van Beek EJ, Timmis AD and Newby DE. Symptoms and quality of life in patients with suspected angina undergoing CT coronary angiography: a randomised controlled trial. Heart (British Cardiac Society). 2017;103:995-1001. 30. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen T, Escaned J, Gersh BJ, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, Valgimigli M, Achenbach S, Bax JJ and Group ESCSD. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). European Heart Journal. 2019. 31. Rossi A, Uitterdijk A, Dijkshoorn M, Klotz E, Dharampal A, van Straten M, van der Giessen WJ, Mollet N, van Geuns RJ, Krestin GP, Duncker DJ, de Feyter PJ and Merkus D. Quantification of myocardial blood flow by adenosine-stress CT perfusion imaging in pigs during various degrees of stenosis correlates well with coronary artery blood flow and fractional flow reserve. European heart journal cardiovascular Imaging. 2013;14:331-8. 32. Brainin P, Frestad D and Prescott E. The prognostic value of coronary endothelial and microvascular dysfunction in subjects with normal or non-obstructive coronary artery disease: A systematic review and meta-analysis. International journal of cardiology. 2018;254:1-9. 33. Ford TJ, Stanley B, Good R, Rocchiccioli P, McEntegart M, Watkins S, Eteiba H, Shaukat A, Lindsay M, Robertson K, Hood S, McGeoch R, McDade R, Yii E, Sidik N, McCartney P, Corcoran D, Collison D, Rush C, McConnachie A, Touyz RM, Oldroyd KG and Berry C. Stratified Medical Therapy Using Invasive Coronary Function Testing in Angina: The CorMicA Trial. J Am Coll Cardiol. 2018;72:2841-2855. 34. Ong P, Camici PG, Beltrame JF, Crea F, Shimokawa H, Sechtem U, Kaski JC and Bairey Merz CN. International standardization of diagnostic criteria for microvascular angina. International journal of cardiology. 2018;250:16-20. 35. Bairey Merz CN, Pepine CJ, Walsh MN and Fleg JL. Ischemia and No Obstructive Coronary Artery Disease (INOCA): Developing Evidence-Based Therapies and Research Agenda for the Next Decade. Circulation. 2017;135:1075-1092. 36. Montone RA, Niccoli G, Fracassi F, Russo M, Gurgoglione F, Camma G, Lanza GA and Crea F. Patients with acute myocardial infarction and non-obstructive coronary arteries: safety and prognostic relevance of invasive coronary provocative tests. Eur Heart J. 2018;39:91-98. 37. Ong P, Athanasiadis A and Sechtem U. Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders. Journal of visualized experiments : JoVE. 2016. Publisher Copyright: © Europa Digital & Publishing 2021. All rights reserved. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021
Y1 - 2021
N2 - This consensus document, a summary of the views of an expert panel organized by the European Association of Percutaneous Cardiovascular Interventions (EAPCI), appraises the importance of ischaemia with non-obstructive coronary arteries (INOCA). Angina pectoris affects approximately 112 million people globally. Up to 70% of patients undergoing invasive angiography do not have obstructive coronary artery disease, more common in women than in men, and a large proportion have INOCA as a cause of their symptoms. INOCA patients present with a wide spectrum of symptoms and signs that are often misdiagnosed as non-cardiac leading to under-diagnosis/investigation and under-treatment. INOCA can result from heterogeneous mechanism including coronary vasospasm and microvascular dysfunction and is not a benign condition. Compared to asymptomatic individuals, INOCA is associated with increased incidence of cardiovascular events, repeated hospital admissions, as well as impaired quality of life and associated increased health care costs. This consensus document provides a definition of INOCA and guidance to the community on the diagnostic approach and management of INOCA based on existing evidence from research and best available clinical practice; noting gaps in knowledge and potential areas for further investigation.
AB - This consensus document, a summary of the views of an expert panel organized by the European Association of Percutaneous Cardiovascular Interventions (EAPCI), appraises the importance of ischaemia with non-obstructive coronary arteries (INOCA). Angina pectoris affects approximately 112 million people globally. Up to 70% of patients undergoing invasive angiography do not have obstructive coronary artery disease, more common in women than in men, and a large proportion have INOCA as a cause of their symptoms. INOCA patients present with a wide spectrum of symptoms and signs that are often misdiagnosed as non-cardiac leading to under-diagnosis/investigation and under-treatment. INOCA can result from heterogeneous mechanism including coronary vasospasm and microvascular dysfunction and is not a benign condition. Compared to asymptomatic individuals, INOCA is associated with increased incidence of cardiovascular events, repeated hospital admissions, as well as impaired quality of life and associated increased health care costs. This consensus document provides a definition of INOCA and guidance to the community on the diagnostic approach and management of INOCA based on existing evidence from research and best available clinical practice; noting gaps in knowledge and potential areas for further investigation.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85100279843&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/32624456
U2 - 10.4244/EIJY20M07_01
DO - 10.4244/EIJY20M07_01
M3 - Review article
C2 - 32624456
VL - 16
SP - 1049
EP - 1069
JO - EuroIntervention
JF - EuroIntervention
SN - 1774-024X
IS - 13
ER -